All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 5th May 2017, pembrolizumab (KEYTRUDA®) was approved by the European Commission (EC) to treat adult patients with R/R cHL who progressed after receiving ASCT and brentuximab vedotin (ADCETRIS®), or who are transplant-ineligible and have failed brentuximab vedotin.
The approval is based on results of the phase Ib KEYNOTE-013 (NCT01953692) trial and the phase II KEYNOTE-087 (NCT02453594) trial, and follows a ‘positive opinion’ granted by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP), which the Lymphoma Hub reported on in March. Our previous report included results of the KEYNOTE-087 trial.
Before awarding the approval, the EC also assessed safety data from 3,194 patients with advanced Melanoma, NSCLC, and cHL included in numerous clinical trials who were administered pembrolizumab at either: 2mg/kg every 3 weeks; 200mg every 3 weeks; or 10mg/kg every 2 or 3 weeks. All-grade AEs experienced by ≥10% of patients included fatigue (22%), pruritus (15%), rash (13%), diarrhea (12%), and nausea (10%). The most serious AEs documented were immune-related adverse reactions and severe infusion-related reactions.
Pembrolizumab (a monoclonal anti-PD-1 IgG4 antibody) is now approved in this indication in all 28 member states of the European Union as well as in Norway, Lichtenstein, and Iceland. Moreover, in March this year, pembrolizumab received an accelerated approval by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients with R/R cHL, which the Lymphoma Hub also reported on.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox